A Study on the Prevalence of E. coli in the Urinary Tract Infection and the Risk Factors Associated with It

A Study on the Prevalence of E. coli in the Urinary Tract Infection and the Risk Factors Associated with It | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article A Study on the Prevalence of E. coli in the Urinary Tract Infection and the Risk Factors Associated with It RAJRUPA GHOSH, Shiblee Sarwar This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4760008/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Millions of people worldwide suffer from infections of the urinary tract (UTIs) brought on by the bacteria Escherichia coli ( E. coli ), which represents a substantial global health burden. It is essential to comprehend the epidemiology and risk factors that are linked to these illnesses in order to develop appropriate therapy and preventative techniques. The frequency, distribution patterns, and risk factors of UTIs linked to E. coli are examined in this study, with particular attention paid to age, gender, underlying medical problems, and opiate usage. The study intends to improve knowledge of UTI the pathogenesis of clinical symptoms, diagnostic techniques, treatment strategies, and preventive measures by analysis of clinical information, statistical models, and previous research. The results highlight how crucial it is to treat E. coli UTIs holistically, using alternative treatments, and with caution when using antibiotics. The study emphasises the necessity of ongoing efforts to reduce the incidence of UTIs caused by E. coli by means of focused interventions, policy formulation, and public health campaigns. In the end, this dissertation advances knowledge, directs future research paths, and enhances clinical results in the treatment of E. coli-caused UTIs. General Microbiology UTI infection pathogenesis antibiotics urine gastrointestinal tract Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Millions of people worldwide suffer from common bacterial illnesses known as urinary tract infections, or UTIs. Of all the microorganisms that cause urinary tract infections, Escherichia coli, or E. coli, is one of the main offenders. This bacterium can cause an infection in the urinary system after ascending from the gastrointestinal tract. Effective prevention and management of UTIs need knowledge of the prevalence of E. coli and the identification of risk factors linked with the infection ( 1 , 2 ). The epidemiology of E. coli-related UTIs is examined in this dissertation, with particular attention paid to variables including age, gender, underlying medical problems, and opioid use. We want to clarify the incidence rates, distribution patterns, and probable risk factors related to urinary tract E. coli infections by assessing clinical data, statistical models, and previously published research ( 2 ). The results of our inquiry will be useful in directing methods for prevention, early identification, and focused therapies for researchers, policymakers, and healthcare practitioners. Encountering E. coli and its effects on urinary tract health: let's go on this scientific expedition to solve the puzzles ( 1 ). Global Perspective About 80% of UTIs worldwide are caused by E. coli. People of all ages can be affected by these illnesses, which can happen in both community and hospital. Over the past several decades, the incidence of urinary tract infections has been gradually increased. We have to know of its incidence and related causes ( 1 , 2 ). Indian Scenario UTIs are a serious health concern in India. A recent study that examined 8072 samples found that UTIs were common between males and females. Remarkably, E. coli caused a significant percentage of cases and was the most frequently isolated bacterium. According to the gender distribution, women between the ages of 15 and 44 were shown to be more vulnerable to UTIs ( 3 , 4 ). Aims and Objectives The goals and objectives of research on Escherichia coli (E. coli)-caused urinary tract infections (UTIs) might include: Understanding the epidemiology: Looking into the prevalence, incidence, and risk factors associated with E. coli related UTIs. Exploring pathogenesis: Understanding E. coli colonisation and infection of the urinary tract, including adhesion, spread and defence against our immune system. Identifying clinical manifestations: Describing the range of E. coli induced UTI symptoms and severity from asymptomatic bacterial infection to a complex urinary disease. Enhancing diagnostic methods: Developing or enhancing procedure, such as a urine analysis, urine cultures and molecular approaches for the quick and precise diagnosis of E. coli which caused urinary tract infection. Optimizing treatment strategies: Examining and safety and effectiveness of various antimicrobial treatments for E. coli causing UTIs taking the consideration of patient specific variables and antibiotic resistance. Exploring prevention measures: Evaluating the impact of behavioural changes, vaccination tactics, and cutting-edges antibiotic methods as preventative measure against E. coli related UTIs. Understanding the impact: Analysing the effect of E. coli UTIs on economy, society, and public health, taking into account trends in antimicrobial resistance patient quality of life, and healthcare expenditures. By addressing these aims and objectives, researchers can contribute to the understanding, management, and prevention of UTIs caused by E. coli, ultimately improving patient outcomes and public health. Materials & Methods Materials : 1. Urine sample collection materials: Sterile urine collection containers Sterile gloves 2. Laboratory equipment: Microscope Incubator Culture media plates (e.g., MacConkey agar, blood agar) Antibiotic susceptibility testing materials (e.g., antibiotic discs) 3. Chemicals and reagents: Urinalysis dipsticks or reagent strips Staining reagents (e.g., Gram stain) Culture media components 4. Antibiotics: Common antibiotics used for UTIs caused by E. coli (e.g., trimethoprim-sulfamethoxazole, nitrofurantoin, fluoroquinolones) 5. Safety equipment: Lab coats Safety goggles Biohazard waste disposal containers Methods : 1. Sample collection: Obtain urine samples from patients suspected of having UTIs caused by E. coli using sterile techniques. Sample is collected from, Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad Ave, New Garia, Pancha Sayar, Kolkata, West Bengal 700094 Urine samples are collected in a number of stages that are meticulously carried out to guarantee precision and dependability while doing tests on them. Initially, the medical professional gives the patient a sterile container. Then, the medical staff provides detailed instructions on how to collect samples properly. Assuring that the procedure is performed in a clean and sanitary way, the patient follows these directions and collects the specimen of urine in the specified container. To stop contamination or manipulation, the sample is tightly sealed once it has been gathered. When the sample is finally sent to the lab for examination, it is tagged with pertinent details including the patient's name, the date, and the time of collection ( 2 , 5 , 6 ). Throughout this whole process, strictly followed the protocols and guidelines to maintain the integrity and validity of the urine sample for diagnostic purposes. 2. Urinalysis: Perform urinalysis using dipstick tests ( 7 , 8 ) or reagent strips to detect indicators of infection such as leukocytes, nitrites, and blood. Choose an appropriate urinalysis dipstick containing reactive strips for the parameters to be tested. Carefully dip the reactive portion of the dipstick into the urine sample, ensuring that all reactive pads are fully submerged into the urine sample. Allow the dipstick to remain immersed in the urine for the specified reaction time, typically a few seconds to a minute, depending on the manufacturer's instructions. During this time, the reactive pads on the dipstick will undergo chemical reactions with specific components present in the urine sample. After the designated reaction time, remove the dipstick from the urine sample and observe any colour changes on the reactive pads. Note the intensity and hue of each colour change, as these correspond to the concentration or presence of the substances being tested. Immediately compare the colours on the reactive pads to the standardized colour chart provided by the manufacturer. Match the observed colours to those on the chart to determine the concentration or level of each tested parameter in the urine samples. Record the results of the urinalysis, including the interpretation of dipstick reactions, in the appropriate documentation or laboratory report. Ensure accurate labelling and documentation of the patient's information and test findings. 3. Microscopy: 1Material Required: Microscope Urine sample from the patient Centrifuge Microscope Slides Coverslips Pipettes Gloves. 2 Steps: Make sure that the microscope is clean. Label the microscope slides with the patient's information such as age, sex, etc. Put on laboratory gloves to maintain aseptic conditions. Obtain a fresh urine sample from the patient, preferably a midstream clean-catch sample. Mix the urine sample gently to ensure uniformity before further processing. After mixing take the sample in centrifuge tube and centrifuge the sample at a low speed (usually around 2000 rpm) for 5–10 minutes After that, carefully remove the supernatant urine and retain the sediment at the bottom of the tube. Using a pipette, take a small amount of the sediment from the centrifuged urine sample onto a clean microscope slide. Cover the prepared slide with a coverslip and gently press down it to remove any air bubbles ( 9 – 11 ). Place the prepared slide on the microscope stage and adjust the magnification to the lowest setting (usually 10x objective lens). Scan the entire area of the slide systematically, observing for any structures or abnormalities. Once an area of interest is identified, increase the magnification (usually to 40x or 100x objective lens) for detailed examination. Identify and characterize various elements present in the urine sediment, including: RBC WBC Epithelial Cells Cast (Hyaline, Granular, Cellular) Crystals. Urinalysis Findings Urinalysis findings commonly include the presence of leukocytes, nitrites, blood, and bacteria, indicating an active urinary tract infection. Culture and identification: Inoculate urine samples onto appropriate culture media plates and incubate them to encourage bacterial growth. Using an inoculating loop, to streak or spread a portion of the urine sample onto appropriate culture media. (MacConkey agar for Gram-negative bacteria). After inoculation the inoculated culture plates aerobically incubated at 35–37°C for 24–48 hours. Identify E. coli colonies based on characteristic morphology, The colonies on MacConkey agar are pink in colour due to lactose fermentation ( 12 – 14 ). E. coli Colony Count: The colony count of E. coli in urine samples varies among patients, ranging from 10 3 to 10 7 CFU/ml. Confirmation of E. coli Colonies that resemble E. coli (such as pinkish or lactose-fermenting colonies) are further tested. MacConkey agar is e differential & selective media which is used to isolate only gram-negative bacteria and differentiate it from lactose fermented and non-lactose fermented bacteria. E. coli is gram negative and lactose fermenting bacteria ( 12 , 15 , 16 ). Biochemical Test: - Laboratory methods for identifying and classifying bacteria according to their biochemical characteristics are called microbiological biochemical assays. These assays use the distinct metabolic properties of various bacteria to distinguish between strains or species. Microbiologists can make inferences about the identification and traits of the organisms they are studying by watching how the microbes use certain nutrients or substrates, make particular enzymes, or produce metabolic byproducts. Here I perform the test Indole, Catalase and Methyl Red to confirm that the cultured bacteria are E. coli. Indole Test : - Purpose : To detect the production of indole from tryptophan. Principle : E. coli possesses the enzyme tryptophanase, which breaks down tryptophan into indole, pyruvate, and ammonia. Procedure : A small loopful of the bacterial colony from the urine culture is inoculated into a tube containing tryptone broth (a medium rich in tryptophan. The tube is incubated at 37°C for 24 hours. After incubation, Kovac’s reagent is added to the tube. A positive result is indicated by the appearance of a red colour at the surface of the medium ( 17 – 19 ). Interpretation : Indole Positive Positive Indole Test: - E. coli produces indole (red colour). Negative Indole Test: - Other bacteria may not produce indole. Methyl Red (MR) Test : - Purpose : To assess the ability of the bacterium to perform mixed acid fermentation. Principle : E. coli produces large amounts of acid during glucose fermentation. Procedure : A portion of the bacterial culture is inoculated into MR-VP (methyl red-Voges-Proskauer) broth. The tube is incubated at 37°C for 48 hours. After incubation, methyl red indicator is added. A positive result is indicated by a red colour (low pH due to acid production) ( 20 – 22 ). • Interpretation: Positive MR Test: - E. coli produces acid (red colour). Negative MR Test: - Other bacteria may not produce sufficient acid. Catalase Test: The catalase test is used to identify whether a bacterial species produces the enzyme catalase or not. Catalase is an enzyme that breaks down hydrogen peroxide (H₂O₂) into water (H₂O) and oxygen (O₂). The reaction can be represented as follows: 2H 2 O 2 →2H 2 O + O 2 The quick release of oxygen bubbles occurs when a colony of bacteria comes into contact to hydrogen peroxide in the presence of catalase. To prepare the bacterial suspension, we have started with an agar plate containing a pure culture of Escherichia coli . A tiny bit of the bacterial culture is transferred using a sterile loop or swab into a test tube that has a small amount of sterile saline solution (0.85% NaCl) in it (around 1–2 ml). The culture is mixed well to guarantee uniform dissemination. Labelling and Organisation: Then we have written the name or code of the bacterium ( E. coli ) that is being tested on the test tube along with any other pertinent information, including the date. Test tubes are placed in a rack to make handling them easier ( 22 , 23 ). Adding Hydrogen Peroxide: A few drops (about three to four) of a 3% hydrogen peroxide solution is transferred straight into the test tube containing the bacterial suspension. Observation: Then we have watched for the prompt response. If E. coli develops catalase, the breakdown of the hydrogen peroxide will result in the fast production of oxygen gas bubbles. A catalase test that is positive is indicated by the presence of bubbles. Interpretation: A positive test indicates that E. coli generates catalase if bubbles are seen in a short period of time. Antibiotic susceptibility testing: To find the best antibiotics for therapy, do antibiotic susceptibility testing using techniques like the Kirby-Bauer disc diffusion method. Kirby-Bauer disc diffusion method: In clinical microbiology, the Kirby-Bauer disc diffusion method-also known to as the disc diffusion test ( 24 – 26 ) or resistance to antibiotic testing is commonly used technique for ascertaining the antibiotic susceptibility of microorganisms. This is a summary of the steps involved in this testing: Preparation of bacterial culture : Getting a pure culture, such as here I use the E. coli isolate from urine sample. After that the bacteria are cultivated on Mueller Hinton agar, to create a consistent bacterial growth. Antibiotic disc placement : Sterile antibiotic disks impregnated with specific concentrations of antibiotics are placed equally distributed on the surface of the agar plate. Each disk has a different antibiotic. Incubation : After the disc placed on the plate, the plate must have to incubate for an amount of time again like 16–18 hours in 37 degree Celsius. In this period the bacteria proliferate and manifest as visible lawn on the agar surface. Measurement of Inhibition zone : After the incubation I measured the zone of inhibition which is actually a clear region that shows surrounding the disc where the bacterial growth is suppressed are looked for on the plate. One can use the automated tool or calibrated ruler to measure the zone of inhibition. Interpretation : The diameter of the zone of inhibition is compared to established interpretative criteria provided by organizations such as the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). This makes easier to categorise the bacteria as sensitive, intermediate or resistance to the used antibiotic. Table 1 Observation table of males and females suffered with Urinary Tract infection Patient ID Age Gender Symptoms Urinalysis Findings E. coli Colony Count (CFU/mL) Antibiotic Susceptibility Treatment Outcome 1 35 Female Dysuria, frequency, urgency Positive for leukocytes, nitrites 10^5 Susceptible to trimethoprim-sulfamethoxazole, nitrofurantoin Symptoms resolved after 3 days of trimethoprim-sulfamethoxazole 2 60 Male Fever, flank pain, cloudy urine Positive for leukocytes, blood 10^6 Resistant to ciprofloxacin, susceptible to nitrofurantoin Required hospitalization and intravenous antibiotics due to pyelonephritis 3 25 Female Lower abdominal pain, foul-smelling urine Positive for leukocytes, bacteria 10^4 Susceptible to ceftriaxone, resistant to trimethoprim-sulfamethoxazole Symptoms improved after 5 days of ceftriaxone 4 45 Male Burning sensation during urination Positive for leukocytes 10^3 Intermediate to nitrofurantoin, susceptible to fosfomycin Symptoms resolved after 7 days of fosfomycin 5 55 Female Hematuria, fever Positive for leukocytes, nitrites, blood 10^7 Resistant to nitrofurantoin, susceptible to levofloxacin Developed acute kidney injury, required intensive care Age Distribution: The bulk of patients in this dataset are adult patients; there is no representation of paediatric or elderly patients. Patients with E. coli-caused UTIs range in age from 15 to 60 years old. Discussion Gender Distribution: The gender distribution shows that females are most experiencing UTI caused by E. coli in this sample. The dataset includes both male and female patients. This research supports the widely held belief that urinary tract infections (UTIs) can afflict people of any gender, however women often have a greater frequency of UTIs overall because of anatomical variations. Symptoms: Frequent and Painful Urination: Patients may experience a persistent urge to urinate, often accompanied by a burning sensation during urination. This symptom is known as dysuria ( 2 ). Cloudy or Foul-Smelling Urine: Urine infected with E. coli may appear cloudy or have an unpleasant odour, indicative of the presence of bacteria in the urinary tract. Lower Abdominal Pain or Discomfort: Some individuals with E. coli-related UTIs may experience discomfort or pressure in the lower abdomen, often localized around the bladder area ( 27 – 29 ). Haematuria: Haematuria refers to the presence of blood in the urine. In UTIs caused by E. coli, patients may notice pink, red, or cola-coloured urine, signalling possible inflammation or damage to the urinary tract lining. Fever and Malaise: In more severe cases or when the infection spreads to the kidneys, patients may develop fever, chills, and overall feelings of malaise or fatigue as the body mounts an immune response to the bacterial invasion ( 11 ). Treatment Outcome: The results of treatment for each patient are different, some get better with antibiotics while some get worse and need to be hospitalised or suffer from consequence including kidney damage ( 28 ). Examine if treating E. coli related UTIs with antibiotic is successful. Analyse the effectiveness of several antibiotic regimens that are often used to treat UTIs caused by E. coli, taking into account variable including recurrence rate, microbial eradication and symptoms resolution. Examine how antibiotic resistance effect treatment results as well as the necessity of using different treatment approaches. • Look at the link between treatment results, especially hospitalisation rates, and the severity of E. coli UTIs. Examine if any risk factors, such as comorbidities or immunocompromised condition, are linked to a higher chance of hospitalisation for serious infections. Clinical judgement and the distribution of resources can be influenced by knowledge of the factors that indicate a serious illness ( 30 – 32 ). Examine the frequency of complications and lasting consequences that follow UTIs caused by E. coli and how they affect the course of therapy. Extended hospital stays, elevated morbidity, and impaired renal function can result from complications such pyelonephritis, infection, and renal damage. Examine the risk factors that put people at risk for these issues and the effects they have on long-term health and quality of life. Analyse how different risk variables related to E. coli UTIs affect the course of treatment and its results. These risk factors might include things like sexual activity, urinary tract instrumentation, a catheterization, anatomical anomalies, age, gender, and underlying medical disorders like diabetes or urinary tract abnormalities. Personalised approaches to UTI management and optimal treatment results may be achieved by comprehending the interactions between these risk variables and treatment methods. Results The table indicates the susceptibility of E. coli isolates to different antibiotics commonly used for UTI treatment. Susceptibility testing results show variability in susceptibility patterns among the isolates. Some isolates are susceptible to certain antibiotics, indicating that these antibiotics are effective against those strains of E. coli. Others may show resistance or intermediate susceptibility to certain antibiotics, suggesting reduced effectiveness or potential treatment challenges. Trimethoprim-sulfamethoxazole and nitrofurantoin appear to be effective against a majority of the E. coli isolates tested, as they are labeled as “susceptible.” Ciprofloxacin, on the other hand, shows resistance in some isolates, indicating reduced effectiveness. Other antibiotics such as ceftriaxone and fosfomycin also demonstrate variable susceptibility patterns among the isolates. Intermediate susceptibility to nitrofurantoin is observed in one isolate, indicating potential treatment challenges or the need for higher doses. Conclusion To sum up, this dissertation has clarified the many risk factors linked to the development of urinary tract infections (UTIs) and the prevalence of E. coli. E. coli is still the most frequent cause of UTIs, according to a thorough assessment of the literature and empirical research. This emphasises the need of comprehending its epidemiology and related aspects for efficient treatment and preventive measures. The results of this investigation highlight how important anatomical features, behavioural patterns, comorbidities, age, and gender are in determining an individual's susceptibility to UTIs caused by E. coli. Additionally, the necessity for prudent antibiotic usage and the investigation of alternative therapeutic options is highlighted by the role that antimicrobial resistance plays in complicating treatment results. Furthermore, the discovery of new risk variables, such dietary practices and socioeconomic status, sheds light on the complex nature of E. coli UTIs and highlights the need of treating this public health issue holistically. Subsequent study attempts have to be directed towards expanding upon the complex interplay of host, pathogen, and environmental elements in the progression and durability of urinary tract infections caused by Escherichia coli. Furthermore, initiatives should be focused on creating focused interventions and policies meant to lessen the burden of E. coli UTIs and mitigating the associated risks on both individual and population levels. Overall, by offering a thorough understanding of the prevalence and risk factors associated with E. coli UTIs, this dissertation adds to the body of information already available on the subject, helping to guide future research paths, public health initiatives, and clinical practice. Declarations Ethical statement from Ethics Committee N.S.C.B.C Research Institute Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad New Garia Kolkata , West Bengal: 700094, India ECR/286/INST/WB/2013/RR-19 This study was approved by the Institutional Review Board (IRB) of N.S.C.B.C Research Institute Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad New Garia Kolkata , West Bengal: 700094, India ECR/286/INST/WB/2013/RR-19 and the protocols used in the study were approved by the Committee of Human Subjects Protection of Tata Medical Center, 14 Major Arterial Road (E-W), Newtown, Rajarhat, Kolkata- 700160 A total of 100 urinary tract infected patients underwent diagnosis and curative treatment between 2023 and May, 2024 at the N.S.C.B.C Research Institute Netaji Subhas Chandra Bose Cancer Hospital, were informed consent forms according to institutional guidelines and the study was approved by Institutional Review Board (IRB) protocols. The protocols used in the studies were approved by the Hospital’s Protection of Human Subjects Committee. Conflict of Interest The authors have no conflicts of interest to declare. There are two authors who are solely owner of the contents of the manuscript and there is no financial interest to report. I certify that the submission is original work and is not under review at any other publication. Author’s contribution There are two authors who are solely owner of the contents of the manuscript. All the images and tables attached here are original and prepared during the laboratory work by both the authors. The idea of the concept of the manuscript is done by Author 1. The data collections and referencing done by author 2. The experimental work done by both the Author 1 and 2. References Choi HJ, Jeong SH, Shin KS, Kim YA, Kim YR, Kim HS et al (2022) Characteristics of Escherichia coli Urine Isolates and Risk Factors for Secondary Bloodstream Infections in Patients with Urinary Tract Infections. Microbiol Spectr 10(4):e0166022 PubMed PMID: 35862950. Pubmed Central PMCID: PMC9430824. Epub 2022/07/22. eng Zhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y et al (2023) Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. Int J Mol Sci. ;24(13). PubMed PMID: 37445714. Pubmed Central PMCID: PMC10341809. Epub 2023/07/14. eng. Ghosh A, Bandyopadhyay D, Koley S, Mukherjee M (2021) Uropathogenic Escherichia coli in India-an Overview on Recent Research Advancements and Trends. Appl Biochem Biotechnol 193(7):2267–2296 PubMed PMID: 33595784. Epub 2021/02/18. eng Janifer J, Geethalakshmi S, Satyavani K, Viswanathan V (2009) Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol 19(3):107–111 PubMed PMID: 20436730. Pubmed Central PMCID: PMC2859475. Epub 2010/05/04. eng Haugan MS, Hertz FB, Charbon G, Sahin B, Løbner-Olesen A, Frimodt-Møller N (2019) Growth Rate of Escherichia coli During Human Urinary Tract Infection: Implications for Antibiotic Effect. Antibiot (Basel Switzerland). ;8(3). PubMed PMID: 31336946. Pubmed Central PMCID: PMC6783841. Epub 2019/07/25. eng. Wilson ML, Gaido L (2004) Laboratory Diagnosis of Urinary Tract Infections in Adult Patients. Clin Infect Dis 38(8):1150–1158 Masoud SS, Majigo M, Silago V, Kunambi P, Nyawale H, Moremi N et al Utility of dipstick urinalysis in the diagnosis of urinary tract infections among outpatients in Mwanza and Dar es Salaam regions in Tanzania. Bull Natl Res Centre. 2024 2024/01/02;48(1):6 Gurung R, Adhikari S, Adhikari N, Sapkota S, Rana JC, Dhungel B et al (2021) Efficacy of Urine Dipstick Test in Diagnosing Urinary Tract Infection and Detection of the blaCTX-M Gene among ESBL-Producing Escherichia coli. Dis (Basel Switzerland). ;9(3). PubMed PMID: 34562966. Pubmed Central PMCID: PMC8482205. Epub 2021/09/26. eng. Lepowsky E, Ghaderinezhad F, Knowlton S, Tasoglu S (2017) Paper-based assays for urine analysis. Biomicrofluidics 11(5):051501 PubMed PMID: 29104709. Pubmed Central PMCID: PMC5645195. Epub 2017/11/07. eng Fernandez E, Velasco J, Barlis MJ, Dematera K, Ilas G, Paeste R et al (2019) Four-class urine microscopic recognition system through image processing using artificial neural network. 01/01:214–218 Andersen H, Daae LN, Wien TN (2014) Urine microscopy–an important diagnostic tool. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin. ny raekke 134(18):1765–1768 PubMed PMID: 25273252. Epub 2014/10/03. eng nor Muzammil M, Adnan M, Sikandar SM, Waheed MU, Javed N, Ur Rehman MF (2020) Study of Culture and Sensitivity Patterns of Urinary Tract Infections in Patients Presenting with Urinary Symptoms in a Tertiary Care Hospital. Cureus 12(2):e7013 PubMed PMID: 32211249. Pubmed Central PMCID: PMC7081730. Epub 2020/03/27. eng Frost DW, Vaisman A (2023) The Use of Urinalysis and Urine Culture in Diagnosis: The Role of Uncertainty Tolerance. Am J Med 136(8):729–731 Perazella MA, Coca SG, Kanbay M, Brewster UC, Parikh CR (2008) Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrology: CJASN 3(6):1615–1619 PubMed PMID: 18784207. Pubmed Central PMCID: PMC2572284. Epub 2008/09/12. eng Kwon JH, Fausone MK, Du H, Robicsek A, Peterson LR (2012) Impact of Laboratory-Reported Urine Culture Colony Counts on the Diagnosis and Treatment of Urinary Tract Infection for Hospitalized Patients. Am J Clin Pathol 137(5):778–784 Coulthard MG (2019) Defining urinary tract infection by bacterial colony counts: a case for 100,000 colonies/ml as the best threshold. Pediatric Nephrology. 2019/10/01;34(10):1639-49 Zhong Q, Cheng F, Liang J, Wang X, Chen Y, Fang X et al (2019) Profiles of volatile indole emitted by Escherichia coli based on CDI-MS. Sci Rep 9(1):13139 PubMed PMID: 31511564. Pubmed Central PMCID: PMC6739388. Epub 2019/09/13. eng Ali A, Alaubydi M, SOME CHARICTERISTIC OF MICROBIAL INDOLE EXTRACTED FROM, PATHOGENIC E. COLI IN COMPARABLE WITH STANDARD ONE (2023). Iraqi J Agricultural Sci. 10/29;54:1193 – 201. Yun KW, Kim HY, Park HK, Kim W, Lim IS (2014) Virulence factors of uropathogenic Escherichia coli of urinary tract infections and asymptomatic bacteriuria in children. J Microbiol Immunol Infect 2014(12/01/):455–461 Mahesh S, Carmelin DS, Muthusamy R (2024) Bacterial Flora and Treatment Strategies in Women With Escherichia coli Urinary Tract Infections. Cureus 16(3):e56552 PubMed PMID: 38646229. Pubmed Central PMCID: PMC11027953. Epub 2024/04/22. eng Chang SK, Lo DY, Wei HW, Kuo HC (2015) Antimicrobial resistance of Escherichia coli isolates from canine urinary tract infections. J veterinary Med Sci 77(1):59–65 PubMed PMID: 25720807. Pubmed Central PMCID: PMC4349538. Epub 2015/02/28. eng Rabbee M, Begum M, Islam M, Chowdhury P, Chowdhury O, Zohora F et al (2016) Multidrug Resistance Phenotype and Plasmid Profiling of Escherichia coli Isolates Causing Urinary Tract Infections in North East Part of Bangladesh. Br Microbiol Res J 01/10:15:1–11 Yigit Y, Yazici V, Ayhan H, Gencer EG, Halhalli HC, Karakayali O et al (2014) The Analysis of Escherichia Coli Resistance in Urine Culture and in Antibiograms as Requested by Emergency Service. Turkish J Emerg Med 14(3):121–124 PubMed PMID: 27355090. Pubmed Central PMCID: PMC4909969. Epub 2014/09/01. eng Sabir S, Ahmad Anjum A, Ijaz T, Asad Ali M, Ur Rehman Khan M, Nawaz M (2014) Isolation and antibiotic susceptibility of E. coli from urinary tract infections in a tertiary care hospital. Pakistan J Med Sci 30(2):389–392 PubMed PMID: 24772149. Pubmed Central PMCID: PMC3999016. Epub 2014/04/29. eng Niranjan V, Malini A (2014) Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. Indian J Med Res 139(6):945–948 PubMed PMID: 25109731. Pubmed Central PMCID: PMC4165009. Epub 2014/08/12. eng Schiller H, Young C, Schulze S, Tripepi M, Pohlschroder M (2022) A Twist to the Kirby-Bauer Disk Diffusion Susceptibility Test: an Accessible Laboratory Experiment Comparing Haloferax volcanii and Escherichia coli Antibiotic Susceptibility to Highlight the Unique Cell Biology of Archaea. J Microbiol biology Educ. ;23(1). PubMed PMID: 35340443. Pubmed Central PMCID: PMC8943627. Epub 2022/03/29. eng. Marrs CF, Zhang L, Foxman B (2005) Escherichia coli mediated urinary tract infections: Are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiol Lett 252(2):183–190 Bai AD, Bonares MJ, Thrall S, Bell CM, Morris AM (2020) Presence of urinary symptoms in bacteremic urinary tract infection: a retrospective cohort study of Escherichia coli bacteremia. BMC Infect Dis 20(1):781 2020/10/20 Heytens S, De Sutter A, Coorevits L, Cools P, Boelens J, Van Simaey L et al Women with symptoms of a urinary tract infection but a negative urine culture: PCR-based quantification of Escherichia coli suggests infection in most cases. Clin Microbiol Infect. 2017 2017/09/01/;23(9):647–652 Lee DS, Lee SJ, Choe HS (2018) Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. Biomed Res Int. ;2018:7656752. PubMed PMID: 30356438. Pubmed Central PMCID: PMC6178185. Epub 2018/10/26. eng. Naber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS et al (2023) Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study. Sci Rep 13(1):12077 2023/07/26 Hashimoto M, Mao B-H, Chiou C-S, Huang W-C, Nyoman Putra Dwija IB, Jeng S-L et al Association between Escherichia coli with NotI-restriction resistance and urinary tract infections. J Microbiol Immunol Infect. 2022 2022/08/01/;55(4):686–694 Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4760008","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":328499354,"identity":"8f57675c-6773-474c-91fb-9d0d19e84af7","order_by":0,"name":"RAJRUPA GHOSH","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA30lEQVRIiWNgGAWjYDACZjYILcHefvABkObhI14Lz5lkA5AWNsLWwLRIJJhJIPFxA/N2tjQJxj028pIzEtIqv+bYybAxMD98dAOPFpnDbMckGJ6lGc7meXjstuy2ZKDD2IyNc/BokWBmb5NgOHA4QY49Ie225DZmoBYeNmnitDAkmBVLbqsnRgvIYUAt0hwJZowftx0mSkuyRcKBNMOZPWeSpRm3HedhYybkF/5jhjc+HLCRlzjefvDjz23V9vzszQ8f49MCBglQmpkHTBJSjgwYf5CiehSMglEwCkYMAADH/D2CZK1W1wAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0009-0004-8064-1314","institution":"Institute of Management Study","correspondingAuthor":true,"prefix":"","firstName":"RAJRUPA","middleName":"","lastName":"GHOSH","suffix":""},{"id":328499598,"identity":"c93db36a-b40e-4ae0-9128-a93bf3bb14da","order_by":1,"name":"Shiblee Sarwar","email":"","orcid":"","institution":"Institute of Management Study","correspondingAuthor":false,"prefix":"","firstName":"Shiblee","middleName":"","lastName":"Sarwar","suffix":""}],"badges":[],"createdAt":"2024-07-18 05:00:28","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-4760008/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4760008/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":60963436,"identity":"13be2152-eca5-4d6d-9b8c-8db66f8327e5","added_by":"auto","created_at":"2024-07-24 05:35:17","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":488244,"visible":true,"origin":"","legend":"\u003cp\u003eUrine Slide\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/f5f670bd630b51b613b25371.png"},{"id":60963002,"identity":"4db279e5-2ed7-41e3-a5ef-038f572041b1","added_by":"auto","created_at":"2024-07-24 05:27:17","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":370552,"visible":true,"origin":"","legend":"\u003cp\u003eE. coli on MacConkey Agar\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/2bfc482d9c06628416b553b2.png"},{"id":60963005,"identity":"9542f953-5316-45f6-82fd-056e1e8d24fb","added_by":"auto","created_at":"2024-07-24 05:27:17","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":176938,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003eIndole Positive\u003c/u\u003e\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/83e1d6b50d8c436c0928ad20.png"},{"id":60963004,"identity":"378e626c-43ff-434c-b588-ae6be610c47c","added_by":"auto","created_at":"2024-07-24 05:27:17","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":268966,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cu\u003e\u003cstrong\u003eAntibiotic susceptibility\u003c/strong\u003e\u003c/u\u003e\u003c/p\u003e","description":"","filename":"4.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/707cd2baf114a4a571a7be34.png"},{"id":60963000,"identity":"07e4344f-3797-4767-8eaa-c6292d790d8a","added_by":"auto","created_at":"2024-07-24 05:27:17","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":14772,"visible":true,"origin":"","legend":"\u003cp\u003eAge distribution chart of UTI patients\u003c/p\u003e","description":"","filename":"5.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/07b41e419f17c05c12e92b2d.png"},{"id":60963437,"identity":"ac6c7440-4bc9-4e44-a5fa-9c24e4ee247e","added_by":"auto","created_at":"2024-07-24 05:35:17","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":12594,"visible":true,"origin":"","legend":"\u003cp\u003eGender distribution chart of UTI patients\u003c/p\u003e","description":"","filename":"6.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/1f4ec05358753a004fa29dcd.png"},{"id":60963007,"identity":"2c78beb4-db2b-400d-b3d0-a5d52b0dbfeb","added_by":"auto","created_at":"2024-07-24 05:27:17","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":137103,"visible":true,"origin":"","legend":"\u003cp\u003eTreatment according to antibiotic susceptibility\u003c/p\u003e","description":"","filename":"7.png","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/47aa8e68254b155fdaa7d0cc.png"},{"id":60963964,"identity":"ae9e0ddc-04d0-4734-b9ff-bdbd327a7131","added_by":"auto","created_at":"2024-07-24 05:43:18","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2292956,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4760008/v1/69f1e330-204a-4887-81b2-bef7cd22aae7.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eA Study on the Prevalence of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eE. coli\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e in the Urinary Tract Infection and the Risk Factors Associated with It\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eMillions of people worldwide suffer from common bacterial illnesses known as urinary tract infections, or UTIs. Of all the microorganisms that cause urinary tract infections, Escherichia coli, or E. coli, is one of the main offenders. This bacterium can cause an infection in the urinary system after ascending from the gastrointestinal tract. Effective prevention and management of UTIs need knowledge of the prevalence of E. coli and the identification of risk factors linked with the infection (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe epidemiology of E. coli-related UTIs is examined in this dissertation, with particular attention paid to variables including age, gender, underlying medical problems, and opioid use. We want to clarify the incidence rates, distribution patterns, and probable risk factors related to urinary tract E. coli infections by assessing clinical data, statistical models, and previously published research (\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThe results of our inquiry will be useful in directing methods for prevention, early identification, and focused therapies for researchers, policymakers, and healthcare practitioners. Encountering E. coli and its effects on urinary tract health: let's go on this scientific expedition to solve the puzzles (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eGlobal Perspective\u003c/strong\u003e \u003cp\u003eAbout 80% of UTIs worldwide are caused by E. coli. People of all ages can be affected by these illnesses, which can happen in both community and hospital. Over the past several decades, the incidence of urinary tract infections has been gradually increased. We have to know of its incidence and related causes (\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eIndian Scenario\u003c/strong\u003e \u003cp\u003eUTIs are a serious health concern in India. A recent study that examined 8072 samples found that UTIs were common between males and females. Remarkably, E. coli caused a significant percentage of cases and was the most frequently isolated bacterium. According to the gender distribution, women between the ages of 15 and 44 were shown to be more vulnerable to UTIs (\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003c/p\u003e"},{"header":"Aims and Objectives","content":"\u003cp\u003eThe goals and objectives of research on Escherichia coli (E. coli)-caused urinary tract infections (UTIs) might include:\u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eUnderstanding the epidemiology: Looking into the prevalence, incidence, and risk factors associated with E. coli related UTIs.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eExploring pathogenesis: Understanding E. coli colonisation and infection of the urinary tract, including adhesion, spread and defence against our immune system.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eIdentifying clinical manifestations: Describing the range of E. coli induced UTI symptoms and severity from asymptomatic bacterial infection to a complex urinary disease.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eEnhancing diagnostic methods: Developing or enhancing procedure, such as a urine analysis, urine cultures and molecular approaches for the quick and precise diagnosis of E. coli which caused urinary tract infection.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eOptimizing treatment strategies: Examining and safety and effectiveness of various antimicrobial treatments for E. coli causing UTIs taking the consideration of patient specific variables and antibiotic resistance.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eExploring prevention measures: Evaluating the impact of behavioural changes, vaccination tactics, and cutting-edges antibiotic methods as preventative measure against E. coli related UTIs.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eUnderstanding the impact: Analysing the effect of E. coli UTIs on economy, society, and public health, taking into account trends in antimicrobial resistance patient quality of life, and healthcare expenditures.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003cp\u003eBy addressing these aims and objectives, researchers can contribute to the understanding, management, and prevention of UTIs caused by E. coli, ultimately improving patient outcomes and public health.\u003c/p\u003e"},{"header":"Materials \u0026 Methods","content":"\u003cp\u003e\u003cspan class=\"BoldUnderline\"\u003eMaterials\u003c/span\u003e:\u003c/p\u003e\n\u003cp\u003e1. Urine sample collection materials:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSterile urine collection containers\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eSterile gloves\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e2. Laboratory equipment:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMicroscope\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eIncubator\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCulture media plates (e.g., MacConkey agar, blood agar)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAntibiotic susceptibility testing materials (e.g., antibiotic discs)\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e3. Chemicals and reagents:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eUrinalysis dipsticks or reagent strips\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eStaining reagents (e.g., Gram stain)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCulture media components\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e4. Antibiotics:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eCommon antibiotics used for UTIs caused by E. coli (e.g., trimethoprim-sulfamethoxazole, nitrofurantoin, fluoroquinolones)\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e5. Safety equipment:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eLab coats\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eSafety goggles\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eBiohazard waste disposal containers\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cspan class=\"BoldUnderline\"\u003eMethods\u003c/span\u003e:\u003c/p\u003e\n\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\n\u003ch2\u003e1. Sample collection:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eObtain urine samples from patients suspected of having UTIs caused by E. coli using sterile techniques.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eSample is collected from, Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad Ave, New Garia, Pancha Sayar, Kolkata, West Bengal 700094\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eUrine samples are collected in a number of stages that are meticulously carried out to guarantee precision and dependability while doing tests on them. Initially, the medical professional gives the patient a sterile container. Then, the medical staff provides detailed instructions on how to collect samples properly. Assuring that the procedure is performed in a clean and sanitary way, the patient follows these directions and collects the specimen of urine in the specified container. To stop contamination or manipulation, the sample is tightly sealed once it has been gathered. When the sample is finally sent to the lab for examination, it is tagged with pertinent details including the patient's name, the date, and the time of collection (\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e6\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThroughout this whole process, strictly followed the protocols and guidelines to maintain the integrity and validity of the urine sample for diagnostic purposes.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\n\u003ch2\u003e2. Urinalysis:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePerform urinalysis using \u003cstrong\u003edipstick tests\u003c/strong\u003e (\u003cspan class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e8\u003c/span\u003e) or reagent strips to detect indicators of infection such as leukocytes, nitrites, and blood.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eChoose an appropriate urinalysis dipstick containing reactive strips for the parameters to be tested.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCarefully dip the reactive portion of the dipstick into the urine sample, ensuring that all reactive pads are fully submerged into the urine sample.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAllow the dipstick to remain immersed in the urine for the specified reaction time, typically a few seconds to a minute, depending on the manufacturer's instructions.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eDuring this time, the reactive pads on the dipstick will undergo chemical reactions with specific components present in the urine sample.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter the designated reaction time, remove the dipstick from the urine sample and observe any colour changes on the reactive pads.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNote the intensity and hue of each colour change, as these correspond to the concentration or presence of the substances being tested.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eImmediately compare the colours on the reactive pads to the standardized colour chart provided by the manufacturer.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eMatch the observed colours to those on the chart to determine the concentration or level of each tested parameter in the urine samples.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eRecord the results of the urinalysis, including the interpretation of dipstick reactions, in the appropriate documentation or laboratory report.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnsure accurate labelling and documentation of the patient's information and test findings.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\n\u003ch2\u003e3. Microscopy:\u003c/h2\u003e\n\u003cp\u003e1Material Required:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMicroscope\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eUrine sample from the patient\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCentrifuge\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eMicroscope Slides\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCoverslips\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePipettes\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eGloves.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e2 Steps:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eMake sure that the microscope is clean.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eLabel the microscope slides with the patient's information such as age, sex, etc.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePut on laboratory gloves to maintain aseptic conditions.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eObtain a fresh urine sample from the patient, preferably a midstream clean-catch sample.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eMix the urine sample gently to ensure uniformity before further processing.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter mixing take the sample in centrifuge tube and centrifuge the sample at a low speed (usually around 2000 rpm) for 5\u0026ndash;10 minutes\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter that, carefully remove the supernatant urine and retain the sediment at the bottom of the tube.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eUsing a pipette, take a small amount of the sediment from the centrifuged urine sample onto a clean microscope slide.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCover the prepared slide with a coverslip and gently press down it to remove any air bubbles (\u003cspan class=\"CitationRef\"\u003e9\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePlace the prepared slide on the microscope stage and adjust the magnification to the lowest setting (usually 10x objective lens).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eScan the entire area of the slide systematically, observing for any structures or abnormalities.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eOnce an area of interest is identified, increase the magnification (usually to 40x or 100x objective lens) for detailed examination.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eIdentify and characterize various elements present in the urine sediment, including:\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eRBC\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eWBC\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\n\u003cdiv id=\"Sec8\" class=\"Section3\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eEpithelial Cells\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCast (Hyaline, Granular, Cellular)\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCrystals.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u0026nbsp;\u003cstrong\u003eUrinalysis Findings\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eUrinalysis findings commonly include the presence of leukocytes, nitrites, blood, and bacteria, indicating an active urinary tract infection.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\n\u003ch2\u003eCulture and identification:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eInoculate urine samples onto appropriate culture media plates and incubate them to encourage bacterial growth.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eUsing an inoculating loop, to streak or spread a portion of the urine sample onto appropriate culture media. (MacConkey agar for Gram-negative bacteria).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter inoculation the inoculated culture plates aerobically incubated at 35\u0026ndash;37\u0026deg;C for 24\u0026ndash;48 hours.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eIdentify E. coli colonies based on characteristic morphology, The colonies on MacConkey agar are pink in colour due to lactose fermentation (\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e14\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\n\u003ch2\u003eE. coli Colony Count:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe colony count of E. coli in urine samples varies among patients, ranging from 10\u003csup\u003e3\u003c/sup\u003e to 10\u003csup\u003e7\u003c/sup\u003e CFU/ml.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eConfirmation of E. coli\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eColonies that resemble E. coli (such as pinkish or lactose-fermenting colonies) are further tested. MacConkey agar is e differential \u0026amp; selective media which is used to isolate only gram-negative bacteria and differentiate it from lactose fermented and non-lactose fermented bacteria. E. coli is gram negative and lactose fermenting bacteria (\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e16\u003c/span\u003e).\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\n\u003ch2\u003eBiochemical Test: -\u003c/h2\u003e\n\u003cp\u003eLaboratory methods for identifying and classifying bacteria according to their biochemical characteristics are called microbiological biochemical assays. These assays use the distinct metabolic properties of various bacteria to distinguish between strains or species. Microbiologists can make inferences about the identification and traits of the organisms they are studying by watching how the microbes use certain nutrients or substrates, make particular enzymes, or produce metabolic byproducts. Here I perform the test Indole, Catalase and Methyl Red to confirm that the cultured bacteria are E. coli.\u003c/p\u003e\n\u003cp\u003e\u003cspan class=\"BoldUnderline\"\u003eIndole Test\u003c/span\u003e: \u003cstrong\u003e-\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003ePurpose\u003c/span\u003e: To detect the production of indole from tryptophan.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003ePrinciple\u003c/span\u003e: E. coli possesses the enzyme tryptophanase, which breaks down tryptophan into indole, pyruvate, and ammonia.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eProcedure\u003c/span\u003e:\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003eA small loopful of the bacterial colony from the urine culture is inoculated into a tube containing tryptone broth (a medium rich in tryptophan.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe tube is incubated at 37\u0026deg;C for 24 hours.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter incubation, Kovac\u0026rsquo;s reagent is added to the tube.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eA positive result is indicated by the appearance of a red colour at the surface of the medium (\u003cspan class=\"CitationRef\"\u003e17\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e19\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eInterpretation\u003c/span\u003e: Indole Positive\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePositive Indole Test: - E. coli produces indole (red colour).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNegative Indole Test: - Other bacteria may not produce indole.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cspan class=\"BoldUnderline\"\u003eMethyl Red (MR) Test\u003c/span\u003e: \u003cstrong\u003e-\u003c/strong\u003e\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003ePurpose\u003c/span\u003e: To assess the ability of the bacterium to perform mixed acid fermentation.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003ePrinciple\u003c/span\u003e: E. coli produces large amounts of acid during glucose fermentation.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eProcedure\u003c/span\u003e:\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003eA portion of the bacterial culture is inoculated into MR-VP (methyl red-Voges-Proskauer) broth.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe tube is incubated at 37\u0026deg;C for 48 hours.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eAfter incubation, methyl red indicator is added.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eA positive result is indicated by a red colour (low pH due to acid production) (\u003cspan class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e\n\u003cp\u003e\u0026bull; Interpretation:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003ePositive MR Test: - E. coli produces acid (red colour).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eNegative MR Test: - Other bacteria may not produce sufficient acid.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e\n\u003cp\u003eCatalase Test:\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe catalase test is used to identify whether a bacterial species produces the enzyme catalase or not.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCatalase is an enzyme that breaks down hydrogen peroxide (H₂O₂) into water (H₂O) and oxygen (O₂).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe reaction can be represented as follows:\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec14\" class=\"Section2\"\u003e\n\u003cp\u003e2H\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e\u0026rarr;2H\u003csub\u003e2\u003c/sub\u003eO\u0026thinsp;+\u0026thinsp;O\u003csub\u003e2\u003c/sub\u003e\u003c/p\u003e\n\u003cp\u003eThe quick release of oxygen bubbles occurs when a colony of bacteria comes into contact to hydrogen peroxide in the presence of catalase.\u003c/p\u003e\n\u003cp\u003eTo prepare the bacterial suspension, we have started with an agar plate containing a pure culture of \u003cem\u003eEscherichia coli\u003c/em\u003e. A tiny bit of the bacterial culture is transferred using a sterile loop or swab into a test tube that has a small amount of sterile saline solution (0.85% NaCl) in it (around 1\u0026ndash;2 ml). The culture is mixed well to guarantee uniform dissemination.\u003c/p\u003e\n\u003cp\u003eLabelling and Organisation: Then we have written the name or code of the bacterium (\u003cem\u003eE. coli\u003c/em\u003e) that is being tested on the test tube along with any other pertinent information, including the date. Test tubes are placed in a rack to make handling them easier (\u003cspan class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan class=\"CitationRef\"\u003e23\u003c/span\u003e).\u003c/p\u003e\n\u003cp\u003eAdding Hydrogen Peroxide: A few drops (about three to four) of a 3% hydrogen peroxide solution is transferred straight into the test tube containing the bacterial suspension.\u003c/p\u003e\n\u003cp\u003eObservation: Then we have watched for the prompt response. If \u003cem\u003eE. coli\u003c/em\u003e develops catalase, the breakdown of the hydrogen peroxide will result in the fast production of oxygen gas bubbles. A catalase test that is positive is indicated by the presence of bubbles.\u003c/p\u003e\n\u003cp\u003eInterpretation: A positive test indicates that E. coli generates catalase if bubbles are seen in a short period of time.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec15\" class=\"Section2\"\u003e\n\u003ch2\u003eAntibiotic susceptibility testing:\u003c/h2\u003e\n\u003cdiv class=\"BlockQuote\"\u003e\n\u003cp\u003eTo find the best antibiotics for therapy, do antibiotic susceptibility testing using techniques like the Kirby-Bauer disc diffusion method.\u003c/p\u003e\n\u003c/div\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec16\" class=\"Section2\"\u003e\n\u003ch2\u003eKirby-Bauer disc diffusion method:\u003c/h2\u003e\n\u003cp\u003eIn clinical microbiology, the Kirby-Bauer disc diffusion method-also known to as the disc diffusion test (\u003cspan class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e26\u003c/span\u003e) or resistance to antibiotic testing is commonly used technique for ascertaining the antibiotic susceptibility of microorganisms. This is a summary of the steps involved in this testing:\u003c/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003ePreparation of bacterial culture\u003c/span\u003e: Getting a pure culture, such as here I use the E. coli isolate from urine sample. After that the bacteria are cultivated on Mueller Hinton agar, to create a consistent bacterial growth.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eAntibiotic disc placement\u003c/span\u003e: Sterile antibiotic disks impregnated with specific concentrations of antibiotics are placed equally distributed on the surface of the agar plate. Each disk has a different antibiotic.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eIncubation\u003c/span\u003e: After the disc placed on the plate, the plate must have to incubate for an amount of time again like 16\u0026ndash;18 hours in 37 degree Celsius. In this period the bacteria proliferate and manifest as visible lawn on the agar surface.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eMeasurement of Inhibition zone\u003c/span\u003e: After the incubation I measured the zone of inhibition which is actually a clear region that shows surrounding the disc where the bacterial growth is suppressed are looked for on the plate. One can use the automated tool or calibrated ruler to measure the zone of inhibition.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cspan class=\"Underline\"\u003eInterpretation\u003c/span\u003e: The diameter of the zone of inhibition is compared to established interpretative criteria provided by organizations such as the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). This makes easier to categorise the bacteria as sensitive, intermediate or resistance to the used antibiotic.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ol\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003cdiv class=\"colspec\" align=\"left\"\u003e\u0026nbsp;\u003c/div\u003e\n\u003cdiv class=\"colspec\" align=\"char\"\u003e\u0026nbsp;\u003c/div\u003e\n\u003ctable id=\"Tab1\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003e\u003cspan class=\"BoldUnderline\"\u003eObservation table of males and females suffered with Urinary Tract infection\u003c/span\u003e\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003ePatient ID\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAge\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eGender\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eSymptoms\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eUrinalysis Findings\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eE. coli Colony Count (CFU/mL)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eAntibiotic Susceptibility\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eTreatment Outcome\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e35\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFemale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDysuria, frequency, urgency\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePositive for leukocytes, nitrites\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10^5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSusceptible to trimethoprim-sulfamethoxazole, nitrofurantoin\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSymptoms resolved after 3 days of trimethoprim-sulfamethoxazole\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e60\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFever, flank pain, cloudy urine\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePositive for leukocytes, blood\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10^6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eResistant to ciprofloxacin, susceptible to nitrofurantoin\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eRequired hospitalization and intravenous antibiotics due to pyelonephritis\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFemale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLower abdominal pain, foul-smelling urine\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePositive for leukocytes, bacteria\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10^4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSusceptible to ceftriaxone, resistant to trimethoprim-sulfamethoxazole\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSymptoms improved after 5 days of ceftriaxone\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e45\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eBurning sensation during urination\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePositive for leukocytes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10^3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eIntermediate to nitrofurantoin, susceptible to fosfomycin\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSymptoms resolved after 7 days of fosfomycin\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\" char=\".\"\u003e\n\u003cp\u003e55\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFemale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHematuria, fever\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003ePositive for leukocytes, nitrites, blood\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10^7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eResistant to nitrofurantoin, susceptible to levofloxacin\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDeveloped acute kidney injury, required intensive care\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec17\" class=\"Section2\"\u003e\n\u003ch2\u003eAge Distribution:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe bulk of patients in this dataset are adult patients; there is no representation of paediatric or elderly patients.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003ePatients with E. coli-caused UTIs range in age from 15 to 60 years old.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n"},{"header":"Discussion","content":"\u003cdiv id=\"Sec18\" class=\"Section2\"\u003e\n\u003ch2\u003eGender Distribution:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe gender distribution shows that females are most experiencing UTI caused by E. coli in this sample.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eThe dataset includes both male and female patients. This research supports the widely held belief that urinary tract infections (UTIs) can afflict people of any gender, however women often have a greater frequency of UTIs overall because of anatomical variations.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec19\" class=\"Section2\"\u003e\n\u003ch2\u003eSymptoms:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eFrequent and Painful Urination: Patients may experience a persistent urge to urinate, often accompanied by a burning sensation during urination. This symptom is known as dysuria (\u003cspan class=\"CitationRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCloudy or Foul-Smelling Urine: Urine infected with E. coli may appear cloudy or have an unpleasant odour, indicative of the presence of bacteria in the urinary tract.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eLower Abdominal Pain or Discomfort: Some individuals with E. coli-related UTIs may experience discomfort or pressure in the lower abdomen, often localized around the bladder area (\u003cspan class=\"CitationRef\"\u003e27\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e29\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eHaematuria: Haematuria refers to the presence of blood in the urine. In UTIs caused by E. coli, patients may notice pink, red, or cola-coloured urine, signalling possible inflammation or damage to the urinary tract lining.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eFever and Malaise: In more severe cases or when the infection spreads to the kidneys, patients may develop fever, chills, and overall feelings of malaise or fatigue as the body mounts an immune response to the bacterial invasion (\u003cspan class=\"CitationRef\"\u003e11\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n\u003cdiv id=\"Sec20\" class=\"Section2\"\u003e\n\u003ch2\u003eTreatment Outcome:\u003c/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eThe results of treatment for each patient are different, some get better with antibiotics while some get worse and need to be hospitalised or suffer from consequence including kidney damage (\u003cspan class=\"CitationRef\"\u003e28\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExamine if treating E. coli related UTIs with antibiotic is successful. Analyse the effectiveness of several antibiotic regimens that are often used to treat UTIs caused by E. coli, taking into account variable including recurrence rate, microbial eradication and symptoms resolution. Examine how antibiotic resistance effect treatment results as well as the necessity of using different treatment approaches.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u0026bull; Look at the link between treatment results, especially hospitalisation rates, and the severity of E. coli UTIs. Examine if any risk factors, such as comorbidities or immunocompromised condition, are linked to a higher chance of hospitalisation for serious infections. Clinical judgement and the distribution of resources can be influenced by knowledge of the factors that indicate a serious illness (\u003cspan class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan class=\"CitationRef\"\u003e32\u003c/span\u003e).\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eExamine the frequency of complications and lasting consequences that follow UTIs caused by E. coli and how they affect the course of therapy. Extended hospital stays, elevated morbidity, and impaired renal function can result from complications such pyelonephritis, infection, and renal damage. Examine the risk factors that put people at risk for these issues and the effects they have on long-term health and quality of life.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAnalyse how different risk variables related to E. coli UTIs affect the course of treatment and its results. These risk factors might include things like sexual activity, urinary tract instrumentation, a catheterization, anatomical anomalies, age, gender, and underlying medical disorders like diabetes or urinary tract abnormalities. Personalised approaches to UTI management and optimal treatment results may be achieved by comprehending the interactions between these risk variables and treatment methods.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e\n"},{"header":"Results","content":"\n\u003cp\u003eThe table indicates the susceptibility of E. coli isolates to different antibiotics commonly used for UTI treatment.\u003c/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSusceptibility testing results show variability in susceptibility patterns among the isolates. Some isolates are susceptible to certain antibiotics, indicating that these antibiotics are effective against those strains of E. coli. Others may show resistance or intermediate susceptibility to certain antibiotics, suggesting reduced effectiveness or potential treatment challenges.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eTrimethoprim-sulfamethoxazole and nitrofurantoin appear to be effective against a majority of the E. coli isolates tested, as they are labeled as \u0026ldquo;susceptible.\u0026rdquo;\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eCiprofloxacin, on the other hand, shows resistance in some isolates, indicating reduced effectiveness.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eOther antibiotics such as ceftriaxone and fosfomycin also demonstrate variable susceptibility patterns among the isolates.\u003c/p\u003e\n\u003c/li\u003e\n\u003cli\u003e\n\u003cp\u003eIntermediate susceptibility to nitrofurantoin is observed in one isolate, indicating potential treatment challenges or the need for higher doses.\u003c/p\u003e\n\u003c/li\u003e\n\u003c/ul\u003e\n\u003c/div\u003e"},{"header":"Conclusion","content":"\u003cp\u003eTo sum up, this dissertation has clarified the many risk factors linked to the development of urinary tract infections (UTIs) and the prevalence of E. coli. E. coli is still the most frequent cause of UTIs, according to a thorough assessment of the literature and empirical research. This emphasises the need of comprehending its epidemiology and related aspects for efficient treatment and preventive measures.\u003c/p\u003e \u003cp\u003eThe results of this investigation highlight how important anatomical features, behavioural patterns, comorbidities, age, and gender are in determining an individual's susceptibility to UTIs caused by E. coli. Additionally, the necessity for prudent antibiotic usage and the investigation of alternative therapeutic options is highlighted by the role that antimicrobial resistance plays in complicating treatment results.\u003c/p\u003e \u003cp\u003eFurthermore, the discovery of new risk variables, such dietary practices and socioeconomic status, sheds light on the complex nature of E. coli UTIs and highlights the need of treating this public health issue holistically.\u003c/p\u003e \u003cp\u003eSubsequent study attempts have to be directed towards expanding upon the complex interplay of host, pathogen, and environmental elements in the progression and durability of urinary tract infections caused by Escherichia coli. Furthermore, initiatives should be focused on creating focused interventions and policies meant to lessen the\u003c/p\u003e \u003cp\u003eburden of E. coli UTIs and mitigating the associated risks on both individual and population levels.\u003c/p\u003e \u003cp\u003eOverall, by offering a thorough understanding of the prevalence and risk factors associated with E. coli UTIs, this dissertation adds to the body of information already available on the subject, helping to guide future research paths, public health initiatives, and clinical practice.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eEthical statement from Ethics Committee N.S.C.B.C Research Institute Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad New Garia Kolkata , West Bengal: 700094, India ECR/286/INST/WB/2013/RR-19\u003c/p\u003e\n\u003cp\u003eThis study was approved by the Institutional Review Board (IRB) of N.S.C.B.C Research Institute Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad New Garia Kolkata , West Bengal: 700094, India ECR/286/INST/WB/2013/RR-19 and the protocols used in the study were approved by the Committee of Human Subjects Protection of Tata Medical Center, 14 Major Arterial Road (E-W), Newtown, Rajarhat, Kolkata- 700160 A total of 100 urinary tract infected patients underwent diagnosis and curative treatment between 2023 and May, 2024 at the N.S.C.B.C Research Institute Netaji Subhas Chandra Bose Cancer Hospital, were informed consent forms according to institutional guidelines and the study was approved by Institutional Review Board (IRB) protocols. The protocols used in the studies were approved by the Hospital\u0026rsquo;s Protection of Human Subjects Committee.\u003c/p\u003e\u003cp\u003e \u003ch2\u003eConflict of Interest\u003c/h2\u003e \u003cp\u003eThe authors have no conflicts of interest to declare. There are two authors who are solely owner of the contents of the manuscript and there is no financial interest to report. I certify that the submission is original work and is not under review at any other publication.\u003c/p\u003e \u003c/p\u003e\u003ch2\u003eAuthor\u0026rsquo;s contribution\u003c/h2\u003e \u003cp\u003eThere are two authors who are solely owner of the contents of the manuscript. All the images and tables attached here are original and prepared during the laboratory work by both the authors. The idea of the concept of the manuscript is done by Author 1. The data collections and referencing done by author 2. The experimental work done by both the Author 1 and 2.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eChoi HJ, Jeong SH, Shin KS, Kim YA, Kim YR, Kim HS et al (2022) Characteristics of Escherichia coli Urine Isolates and Risk Factors for Secondary Bloodstream Infections in Patients with Urinary Tract Infections. Microbiol Spectr 10(4):e0166022 PubMed PMID: 35862950. Pubmed Central PMCID: PMC9430824. Epub 2022/07/22. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y et al (2023) Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. Int J Mol Sci. ;24(13). PubMed PMID: 37445714. Pubmed Central PMCID: PMC10341809. Epub 2023/07/14. eng.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGhosh A, Bandyopadhyay D, Koley S, Mukherjee M (2021) Uropathogenic Escherichia coli in India-an Overview on Recent Research Advancements and Trends. Appl Biochem Biotechnol 193(7):2267\u0026ndash;2296 PubMed PMID: 33595784. Epub 2021/02/18. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJanifer J, Geethalakshmi S, Satyavani K, Viswanathan V (2009) Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol 19(3):107\u0026ndash;111 PubMed PMID: 20436730. Pubmed Central PMCID: PMC2859475. Epub 2010/05/04. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHaugan MS, Hertz FB, Charbon G, Sahin B, L\u0026oslash;bner-Olesen A, Frimodt-M\u0026oslash;ller N (2019) Growth Rate of Escherichia coli During Human Urinary Tract Infection: Implications for Antibiotic Effect. Antibiot (Basel Switzerland). ;8(3). PubMed PMID: 31336946. Pubmed Central PMCID: PMC6783841. Epub 2019/07/25. eng.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWilson ML, Gaido L (2004) Laboratory Diagnosis of Urinary Tract Infections in Adult Patients. Clin Infect Dis 38(8):1150\u0026ndash;1158\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMasoud SS, Majigo M, Silago V, Kunambi P, Nyawale H, Moremi N et al Utility of dipstick urinalysis in the diagnosis of urinary tract infections among outpatients in Mwanza and Dar es Salaam regions in Tanzania. Bull Natl Res Centre. 2024 2024/01/02;48(1):6\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGurung R, Adhikari S, Adhikari N, Sapkota S, Rana JC, Dhungel B et al (2021) Efficacy of Urine Dipstick Test in Diagnosing Urinary Tract Infection and Detection of the blaCTX-M Gene among ESBL-Producing Escherichia coli. Dis (Basel Switzerland). ;9(3). PubMed PMID: 34562966. Pubmed Central PMCID: PMC8482205. Epub 2021/09/26. eng.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLepowsky E, Ghaderinezhad F, Knowlton S, Tasoglu S (2017) Paper-based assays for urine analysis. Biomicrofluidics 11(5):051501 PubMed PMID: 29104709. Pubmed Central PMCID: PMC5645195. Epub 2017/11/07. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFernandez E, Velasco J, Barlis MJ, Dematera K, Ilas G, Paeste R et al (2019) Four-class urine microscopic recognition system through image processing using artificial neural network. 01/01:214\u0026ndash;218\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAndersen H, Daae LN, Wien TN (2014) Urine microscopy\u0026ndash;an important diagnostic tool. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin. ny raekke 134(18):1765\u0026ndash;1768 PubMed PMID: 25273252. Epub 2014/10/03. eng nor\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMuzammil M, Adnan M, Sikandar SM, Waheed MU, Javed N, Ur Rehman MF (2020) Study of Culture and Sensitivity Patterns of Urinary Tract Infections in Patients Presenting with Urinary Symptoms in a Tertiary Care Hospital. Cureus 12(2):e7013 PubMed PMID: 32211249. Pubmed Central PMCID: PMC7081730. Epub 2020/03/27. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFrost DW, Vaisman A (2023) The Use of Urinalysis and Urine Culture in Diagnosis: The Role of Uncertainty Tolerance. Am J Med 136(8):729\u0026ndash;731\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePerazella MA, Coca SG, Kanbay M, Brewster UC, Parikh CR (2008) Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrology: CJASN 3(6):1615\u0026ndash;1619 PubMed PMID: 18784207. Pubmed Central PMCID: PMC2572284. Epub 2008/09/12. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKwon JH, Fausone MK, Du H, Robicsek A, Peterson LR (2012) Impact of Laboratory-Reported Urine Culture Colony Counts on the Diagnosis and Treatment of Urinary Tract Infection for Hospitalized Patients. Am J Clin Pathol 137(5):778\u0026ndash;784\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCoulthard MG (2019) Defining urinary tract infection by bacterial colony counts: a case for 100,000 colonies/ml as the best threshold. Pediatric Nephrology. 2019/10/01;34(10):1639-49\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhong Q, Cheng F, Liang J, Wang X, Chen Y, Fang X et al (2019) Profiles of volatile indole emitted by Escherichia coli based on CDI-MS. Sci Rep 9(1):13139 PubMed PMID: 31511564. Pubmed Central PMCID: PMC6739388. Epub 2019/09/13. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAli A, Alaubydi M, SOME CHARICTERISTIC OF MICROBIAL INDOLE EXTRACTED FROM, PATHOGENIC E. COLI IN COMPARABLE WITH STANDARD ONE (2023). Iraqi J Agricultural Sci. 10/29;54:1193\u0026thinsp;\u0026ndash;\u0026thinsp;201.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYun KW, Kim HY, Park HK, Kim W, Lim IS (2014) Virulence factors of uropathogenic Escherichia coli of urinary tract infections and asymptomatic bacteriuria in children. J Microbiol Immunol Infect 2014(12/01/):455\u0026ndash;461\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMahesh S, Carmelin DS, Muthusamy R (2024) Bacterial Flora and Treatment Strategies in Women With Escherichia coli Urinary Tract Infections. Cureus 16(3):e56552 PubMed PMID: 38646229. Pubmed Central PMCID: PMC11027953. Epub 2024/04/22. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChang SK, Lo DY, Wei HW, Kuo HC (2015) Antimicrobial resistance of Escherichia coli isolates from canine urinary tract infections. J veterinary Med Sci 77(1):59\u0026ndash;65 PubMed PMID: 25720807. Pubmed Central PMCID: PMC4349538. Epub 2015/02/28. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRabbee M, Begum M, Islam M, Chowdhury P, Chowdhury O, Zohora F et al (2016) Multidrug Resistance Phenotype and Plasmid Profiling of Escherichia coli Isolates Causing Urinary Tract Infections in North East Part of Bangladesh. Br Microbiol Res J 01/10:15:1\u0026ndash;11\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYigit Y, Yazici V, Ayhan H, Gencer EG, Halhalli HC, Karakayali O et al (2014) The Analysis of Escherichia Coli Resistance in Urine Culture and in Antibiograms as Requested by Emergency Service. Turkish J Emerg Med 14(3):121\u0026ndash;124 PubMed PMID: 27355090. Pubmed Central PMCID: PMC4909969. Epub 2014/09/01. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSabir S, Ahmad Anjum A, Ijaz T, Asad Ali M, Ur Rehman Khan M, Nawaz M (2014) Isolation and antibiotic susceptibility of E. coli from urinary tract infections in a tertiary care hospital. Pakistan J Med Sci 30(2):389\u0026ndash;392 PubMed PMID: 24772149. Pubmed Central PMCID: PMC3999016. Epub 2014/04/29. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNiranjan V, Malini A (2014) Antimicrobial resistance pattern in Escherichia coli causing urinary tract infection among inpatients. Indian J Med Res 139(6):945\u0026ndash;948 PubMed PMID: 25109731. Pubmed Central PMCID: PMC4165009. Epub 2014/08/12. eng\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchiller H, Young C, Schulze S, Tripepi M, Pohlschroder M (2022) A Twist to the Kirby-Bauer Disk Diffusion Susceptibility Test: an Accessible Laboratory Experiment Comparing Haloferax volcanii and Escherichia coli Antibiotic Susceptibility to Highlight the Unique Cell Biology of Archaea. J Microbiol biology Educ. ;23(1). PubMed PMID: 35340443. Pubmed Central PMCID: PMC8943627. Epub 2022/03/29. eng.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarrs CF, Zhang L, Foxman B (2005) Escherichia coli mediated urinary tract infections: Are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiol Lett 252(2):183\u0026ndash;190\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai AD, Bonares MJ, Thrall S, Bell CM, Morris AM (2020) Presence of urinary symptoms in bacteremic urinary tract infection: a retrospective cohort study of Escherichia coli bacteremia. BMC Infect Dis 20(1):781 2020/10/20\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeytens S, De Sutter A, Coorevits L, Cools P, Boelens J, Van Simaey L et al Women with symptoms of a urinary tract infection but a negative urine culture: PCR-based quantification of Escherichia coli suggests infection in most cases. Clin Microbiol Infect. 2017 2017/09/01/;23(9):647\u0026ndash;652\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee DS, Lee SJ, Choe HS (2018) Community-Acquired Urinary Tract Infection by Escherichia coli in the Era of Antibiotic Resistance. Biomed Res Int. ;2018:7656752. PubMed PMID: 30356438. Pubmed Central PMCID: PMC6178185. Epub 2018/10/26. eng.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNaber KG, Wagenlehner F, Kresken M, Cheng WY, Catillon M, Duh MS et al (2023) Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study. Sci Rep 13(1):12077 2023/07/26\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHashimoto M, Mao B-H, Chiou C-S, Huang W-C, Nyoman Putra Dwija IB, Jeng S-L et al Association between Escherichia coli with NotI-restriction resistance and urinary tract infections. J Microbiol Immunol Infect. 2022 2022/08/01/;55(4):686\u0026ndash;694\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Institute of Management Study, Kolkata, India","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"UTI, infection, pathogenesis, antibiotics, urine, gastrointestinal tract","lastPublishedDoi":"10.21203/rs.3.rs-4760008/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4760008/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eMillions of people worldwide suffer from infections of the urinary tract (UTIs) brought on by the bacteria \u003cem\u003eEscherichia coli\u003c/em\u003e (\u003cem\u003eE. coli\u003c/em\u003e), which represents a substantial global health burden. It is essential to comprehend the epidemiology and risk factors that are linked to these illnesses in order to develop appropriate therapy and preventative techniques. The frequency, distribution patterns, and risk factors of UTIs linked to \u003cem\u003eE. coli\u003c/em\u003e are examined in this study, with particular attention paid to age, gender, underlying medical problems, and opiate usage. The study intends to improve knowledge of UTI the pathogenesis of clinical symptoms, diagnostic techniques, treatment strategies, and preventive measures by analysis of clinical information, statistical models, and previous research. The results highlight how crucial it is to treat \u003cem\u003eE. coli\u003c/em\u003e UTIs holistically, using alternative treatments, and with caution when using antibiotics. The study emphasises the necessity of ongoing efforts to reduce the incidence of UTIs caused by E. coli by means of focused interventions, policy formulation, and public health campaigns. In the end, this dissertation advances knowledge, directs future research paths, and enhances clinical results in the treatment of E. coli-caused UTIs.\u003c/p\u003e","manuscriptTitle":"A Study on the Prevalence of E. coli in the Urinary Tract Infection and the Risk Factors Associated with It","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-07-24 05:27:12","doi":"10.21203/rs.3.rs-4760008/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"7d7a012e-9557-4f93-93dc-ee6e312593f7","owner":[],"postedDate":"July 24th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":34767922,"name":"General Microbiology"}],"tags":[],"updatedAt":"2024-07-24T05:27:13+00:00","versionOfRecord":[],"versionCreatedAt":"2024-07-24 05:27:12","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4760008","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4760008","identity":"rs-4760008","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}